Establishment and Evaluation of Dual HDAC/BET Inhibitors as Therapeutic Options for Germ Cell Tumors and Other Urological Malignancies

• Published in: Molecular cancer therapeutics Vol. 21; no. 11; pp. 1674 - 1688
• Main Authors: Burmeister, Aaron, Stephan, Alexa, Alves Avelar, Leandro A., Müller, Melanie R., Seiwert, Andrea, Höfmann, Stefan, Fischer, Fabian, Torres-Gomez, Hector, Hoffmann, Michèle J., Niegisch, Guenter, Bremmer, Felix, Petzsch, Patrick, Köhrer, Karl, Albers, Peter, Kurz, Thomas, Skowron, Margaretha A., Nettersheim, Daniel
• Format: Journal Article
• Language: English
• Published: United States American Association for Cancer Research 03.11.2022
• Subjects: Animals; Cell Line, Tumor; Cell Proliferation; Chromatin; Cisplatin - pharmacology; Histone Deacetylase Inhibitors - pharmacology; Histone Deacetylases - metabolism; Humans; Neoplasms, Germ Cell and Embryonal - drug therapy; Small Molecule Therapeutics; Urologic Neoplasms - drug therapy; Urologic Neoplasms - genetics
• ISSN: 1535-7163; 1538-8514; 1538-8514
• DOI: 10.1158/1535-7163.MCT-22-0207

Urological malignancies represent major challenges for clinicians, with annually rising incidences. In addition, cisplatin treatment induced long-term toxicities and the development of therapy resistance emphasize the need for novel therapeutics. In this study, we analyzed the effects of novel histone deacetylase (HDAC) and bromodomain and extraterminal domain-containing (BET) inhibitors to combine them into a potent HDAC-BET-fusion molecule and to understand their molecular mode-of-action. Treatment of (cisplatin-resistant) germ cell tumors (GCT), urothelial, renal, and prostate carcinoma cells with the HDAC, BET, and dual inhibitors decreased cell viability, induced apoptosis, and affected the cell cycle. Furthermore, a dual inhibitor considerably decreased tumor burden in GCT xenograft models. On a molecular level, correlating RNA- to ATAC-sequencing data indicated a considerable induction of gene expression, accompanied by site-specific changes of chromatin accessibility after HDAC inhibitor application. Upregulated genes could be linked to intra- and extra-cellular trafficking, cellular organization, and neuronal processes, including neuroendocrine differentiation. Regarding chromatin accessibility on a global level, an equal distribution of active or repressed DNA accessibility has been detected after HDAC inhibitor treatment, questioning the current understanding of HDAC inhibitor function. In summary, our HDAC, BET, and dual inhibitors represent a new treatment alternative for urological malignancies. Furthermore, we shed light on new molecular and epigenetic mechanisms of the tested epi-drugs, allowing for a better understanding of the underlying modes-of-action and risk assessment for the patient.